Fluorophore-Labeled RNA Cap Compound for Stable mRNA Tracking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cap structures for mRNA have limited availability and performance, affecting the development of mRNA vaccines and drugs, and existing labeling methods for RNA molecules in cells reduce transcription efficiency and stability.
Innovation Solution
A compound for RNA capping that enhances capping efficiency, stability, and expression levels, while also allowing for fluorophore labeling for tracking mRNA dynamics in cells or organisms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If nucleotide triphosphates modified with fluorophores are used for RNA labeling, then labeling effect is achieved, but transcription efficiency and mRNA stability are reduced
Solution Approach 1:
The invention segments the labeling function from the nucleotide triphosphate structure by using cap structures with fluorophores instead of modifying the NTPs themselves. This allows the labeling function to be achieved at the cap level while the NTPs remain unmodified for efficient incorporation by RNA polymerase.
Solution Approach 2:
The cap structure serves as an intermediary that carries the fluorophore label to the mRNA without requiring the NTPs to be modified. The cap structure is incorporated during transcription and remains attached to the 5' end of the mRNA, providing continuous labeling throughout the mRNA lifecycle.
2Measurement precision
If nucleotide triphosphates modified with fluorophores are used for RNA labeling, then labeling effect is achieved, but mRNA stability is reduced
Solution Approach 1:
The labeling function is segmented from the NTP structure and placed on the cap structure instead. This ensures that the fluorophore does not interfere with the mRNA sequence or its interaction with cellular machinery, thereby maintaining mRNA stability while achieving labeling.
Solution Approach 2:
The cap structure acts as an intermediary carrier of the fluorophore, separating the labeling function from the mRNA coding sequence. This intermediary approach protects the mRNA from degradation while providing the desired labeling effect for tracking.
3Adaptability or versatility
If limited cap structures are used, then current technology constraints are maintained, but development of mRNA vaccines and drugs is hindered
Solution Approach 1:
The invention creates cap structures with multiple functions: they maintain the essential capping function for mRNA stability and translation, while also providing labeling capability through integrated fluorophores. This multi-functionality accelerates mRNA vaccine and drug development by enabling simultaneous tracking and functional assessment.
Solution Approach 2:
The invention changes the chemical parameters of cap structures by introducing fluorophore-containing groups at various positions (R0, R1, R2). This creates a family of cap analogs with different fluorescent properties, enabling researchers to select optimal caps for specific applications without limiting development progress.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to the technical field of genetic engineering, and relates to two types of compounds for RNA capping and uses thereof. The compound has a structure as represented by formula (I), can be used as an initiating capped oligonucleotide primer to perform mRNA 5' end capping, and has good capping efficiency and protein expression level; and additionally, because the compound is labelled with a fluorophore, the compound can also be used for detecting and tracking dynamic changes of mRNA in cells and organisms, facilitates researches of a delivery process, pharmacokinetic performance, etc. of mRNA in the cells and organisms, and provides convenience for research of mRNA vaccines/drugs in the cells or organisms.